GSK stock faces patent cliff as oncology strategy takes shape
Published on 11/17/2026 at 11:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGSK outlines its growth path
- Management expects the company to keep growing through the 2028-2030 dolutegravir patent period.
- Long-acting HIV treatments, oncology, respiratory medicines and vaccines are central to the next growth phase.
- GSK plans GBP 1.9 billion of restructuring through 2029, with most savings directed toward research and development.
GSK set out its long-term growth strategy at the Jefferies Global Healthcare Conference on Tuesday, November 17, according to Investing.com, which carried a Reuters report. David Redfern, GSK's president of business development and head of ViiV, described a strategy built around specialty medicines, oncology, respiratory treatments, vaccines and longer-acting HIV therapies.
GSK stock traded at 22.96 euros on Lang & Schwarz at 11:49 CET on Tuesday, November 17, 2026, 0.56 percent below the Xetra close of 23.09 euros on Monday, November 16.
Patent cycle tests the portfolio
The main strategic challenge is the loss of exclusivity for key dolutegravir products. Redfern said U.S. exclusivity for Tivicay and Triumeq ends in April 2028, while Dovato faces the end of U.S. exclusivity in late 2029. European exclusivity for important products is also scheduled to end in 2029.
Management expects the HIV business to decline during the 2028-2030 period, although long-acting products should offset part of the pressure. GSK said it still expects to grow through the patent cycle and has set a long-term sales outlook of more than GBP 40 billion by 2031, compared with current annual sales of roughly GBP 35 billion cited at the conference.
Pipeline and dealmaking remain central
ViiV's Cabenuva is the company's current long-acting HIV treatment. A four-month formulation is being studied in the pivotal CUATRO trial, which management said is fully recruited, with results expected in the second half of next year and a potential launch in 2028. Six-month regimens based on VH-184 and VH-499 are in phase II development, with pivotal studies targeted for around mid-2028.
GSK also highlighted oncology as its most important strategic priority for the next five years. The company said oncology currently contributes about GBP 2 billion in sales and could become several times larger. The Nuvalent acquisition strengthened GSK's lung cancer position, while antibody-drug conjugates licensed from Hansoh are being developed in lung, ovarian and endometrial cancers.
Redfern said GSK retains capacity for further transactions but is not seeking another deal on the scale of its largest recent acquisitions. Smaller transactions in the GBP 2 billion to GBP 3 billion range, with scientific differentiation and some development risk already reduced, fit the current approach.
Restructuring supports research spending
The company's restructuring program is valued at GBP 1.9 billion and runs through 2029. It covers supply-chain changes, service-center consolidation, manufacturing automation and a planned relocation of much of GSK's research workforce from Stevenage to Cambridge. Management said most savings will be reinvested in research and development.
For investors, the conference reinforced the trade-off between near-term patent pressure and a broader specialty portfolio. The growth case depends on new oncology launches, long-acting HIV products, respiratory biologics and vaccines arriving in time to cushion the dolutegravir decline.
GSK plc
- ISIN: GB00BN7SWP63
- Lang & Schwarz quote: 22.96 euros on Tuesday, November 17, 2026, at 11:49 CET
- Xetra close: 23.09 euros on Monday, November 16, 2026
- Daily change: 0.56 percent below the Xetra close
The broader UK market is represented by the FTSE 100.
